Sign in
4

Changes in Ownership

CYTOKINETICS INC Filed Acc 0001127602-24-024083

EVP Research & Development sold 7,300 shares at an average $56.77 ($414,401)

  • EVP Research & Development acquired 5,300 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Malik Fady Ibraham EVP Research & Development 2024-09-17 Option exercise 10b5-1 +5,300 $7.96 $42,188 128,220 D
Malik Fady Ibraham EVP Research & Development 2024-09-17 Sale 10b5-1 −5,300 $56.77 $300,881 122,920 D
Malik Fady Ibraham EVP Research & Development 2024-09-17 Sale 10b5-1 −2,000 $56.76 $113,520 120,920 D
Derivatives
Malik Fady Ibraham EVP Research & Development 2024-09-17 Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 −5,300 31,800 D
Open-market sales · 7,300 sh · avg $56.77 · $414,401
Loading xslF345X05/form4.xml…